Trial result ·
A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This trial tested lanreotide in adults with autosomal dominant polycystic kidney disease (ADPKD). Their disease was stage 2/3, with a measured GFR of 30-89. Drugs of this type reduce liver and kidney cyst volume. Earlier trials gave no steady gain in kidney function. The team asked if lanreotide slows the fall in GFR. People got monthly lanreotide 120 mg shots or a placebo.
What they found
The main goal was not met. The yearly gap in measured GFR between arms was -0.3. Its confidence interval ran from -3.4 to 2.8. A creatinine-based model showed a gain, but other markers did not confirm it. Kidney events and quality-of-life scores were similar in both arms. Gut side effects were more common with lanreotide. Low blood sugar also occurred more often with lanreotide.
What it means for patients
The authors said lanreotide did not slow GFR decline in stage 2/3 ADPKD. They said the creatinine signal is exploratory. They said it must be read with a negative main goal in mind. They said the low blood sugar signal calls for close checks when using lanreotide.
Why it is not certain yet
Recruitment stopped at 144 of 180 planned people, because enrollment was slow. The creatinine signal was not backed by cystatin C or urine creatinine tests. The authors call the low blood sugar signal unexpected.
Source
A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.
PubMed · PMID 42320793We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Polycystic kidney disease publications